Ground-Breaking Discovery Shows Potential for Genetically Modified Virus as Cancer Treatment

Researchers have revealed an ongoing study concentrating on the use of a genetically modified virus for melanoma treatment, with very promising results. Though, there is still more to learn on the topic. Read more.

United States – May 28, 2015 /PressCable/ —

A ground-breaking new study released today details researchers surprising success, being the first to use a genetically modified virus to successfully treat melanoma skin cancer. All patients treated in the first focus group were suffering from advanced forms of malignant melanoma, however the study reports that participants lived an average of 20 months longer compared to those given an alternative.

Specialists at the NHS Royal Marsden Hospital and the Institute of Cancer Research (ICR) confirmed that melanoma skin cancer patients treated with a modified form of HSV (the virus that causes cold sores) exhibited an improved rate of survival. Results also showed that some patients were continuing to respond to the treatment up to three years after receiving it.

When asked about these findings, Kevin Harrington, UK trial leader and professor of biological cancer therapies at the ICR and an honorary consultant at the Royal Marsden, said ““I hope, having worked for two decades in this field, that it really is the start of something really exciting. We hope this is the first of a wave of indications for these sorts of [cancer fighting] agents that we will see coming through in the next decade or so.”

While this new innovation is extremely ground-breaking, questions about its safety and risks of adverse side effects still exist. Nora Markin, a representative for Cancer Cures Investigated, was quoted on the topic:

“We can see, based on this study, that there are no bounds to what science can do when it comes to treating deadly diseases like cancer. But, I can’t help but wonder how safe it is to inject an immune-compromised cancer patient with an extremely infectious virus for treatment purposes. Once more research is completed on this method of treatment, I will feel much better about its use, or rejection.”

To review the full study, visit www.cancercuresinvestigated.com. While on this site, the company invites readers to take full advantage of all available information.

For more information about us, please visit http://www.cancercuresinvestigated.com

Contact Info:
Name: Uma Lee
Email: uma@cancercuresinvestigated.com
Organization: Cancer Cures Investigated
Phone: 1-800-777-4914

Release ID: 83076